Ardestani, M.; Khorsandi, Z.; Keshavarzipour, F.; Iravani, S.; Sadeghi-Aliabadi, H.; Varma, R.S.
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. Pharmaceutics 2022, 14, 2220.
https://doi.org/10.3390/pharmaceutics14102220
AMA Style
Ardestani M, Khorsandi Z, Keshavarzipour F, Iravani S, Sadeghi-Aliabadi H, Varma RS.
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. Pharmaceutics. 2022; 14(10):2220.
https://doi.org/10.3390/pharmaceutics14102220
Chicago/Turabian Style
Ardestani, Mina, Zahra Khorsandi, Fariba Keshavarzipour, Siavash Iravani, Hojjat Sadeghi-Aliabadi, and Rajender S. Varma.
2022. "Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications" Pharmaceutics 14, no. 10: 2220.
https://doi.org/10.3390/pharmaceutics14102220
APA Style
Ardestani, M., Khorsandi, Z., Keshavarzipour, F., Iravani, S., Sadeghi-Aliabadi, H., & Varma, R. S.
(2022). Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. Pharmaceutics, 14(10), 2220.
https://doi.org/10.3390/pharmaceutics14102220